Stephen J. Forman - 20 Jan 2025 Form 4 Insider Report for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Role
Director
Signature
/s/ Stephen Forman
Issuer symbol
LIXT
Transactions as of
20 Jan 2025
Net transactions value
$0
Form type
4
Filing time
22 Jan 2025, 17:27:22 UTC
Previous filing
29 Oct 2024
Next filing
02 Apr 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIXT Options to Purchase Common Stock Award $0 +3,030 $0.000000 3,030 20 Jan 2025 Common 3,030 $2.33 Direct F1
holding LIXT Options to Purchase Common Stock 3,858 20 Jan 2025 Common 3,858 $1.30 Direct
holding LIXT Options to Purchase Common Stock 10,000 20 Jan 2025 Common 10,000 $2.37 Direct
holding LIXT Options to Purchase Common Stock 3,018 20 Jan 2025 Common 3,018 $2.37 Direct
holding LIXT Options to Purchase Common Stock 10,000 20 Jan 2025 Common 10,000 $5.88 Direct
holding LIXT Options to Purchase Common Stock 10,000 20 Jan 2025 Common 10,000 $7.45 Direct
holding LIXT Options to Purchase Common Stock 10,000 20 Jan 2025 Common 10,000 $30.30 Direct
holding LIXT Options to Purchase Common Stock 5,000 20 Jan 2025 Common 5,000 $32.10 Direct
holding LIXT Warrants to Purchase Common Stock 2,105 20 Jan 2025 Common 2,105 $57.00 By Stephen Forman Living Trust
holding LIXT Options to Purchase Common Stock 833 20 Jan 2025 Common 833 $9.00 Direct
holding LIXT Options to Purchase Common Stock 833 20 Jan 2025 Common 833 $66.00 Direct
holding LIXT Warrants to Purchase Common Stock 1,667 20 Jan 2025 Common 1,667 $60.00 By Stephen Forman Living Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective January 20, 2025, the reporting person was granted stock options to purchase an aggregate of 3,030 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.